CL2014002019A1 - Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos. - Google Patents

Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.

Info

Publication number: CL2014002019A1
Authority: CL; Chile
Prior art keywords: pharmaceutical composition; asic1 antibodies; asic1; antibodies; pharmaceutical
Prior art date: 2012-01-31

Application number

CL2014002019A

Other languages

English (en)

Inventor

Lynn Macdonald

Min Gao

Marc R Morra

Nicole M Alessandri-Haber

Michael L Lacroix-Fralish

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-31

Filing date

2014-07-30

Publication date

2015-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002019(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-30 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2015-01-16 Publication of CL2014002019A1 publication Critical patent/CL2014002019A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CL2014002019A 2012-01-31 2014-07-30 Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos. CL2014002019A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201261592837P	2012-01-31	2012-01-31
US201261644038P	2012-05-08	2012-05-08
US201261692925P	2012-08-24	2012-08-24

Publications (1)

Publication Number	Publication Date
CL2014002019A1 true CL2014002019A1 (es)	2015-01-16

Family

ID=47666522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002019A CL2014002019A1 (es)	2012-01-31	2014-07-30	Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.

Country Status (34)

Country	Link
US (3)	US9150648B2 (es)
EP (2)	EP3453723B1 (es)
JP (1)	JP6302844B2 (es)
KR (1)	KR102111941B1 (es)
CN (1)	CN104093738B (es)
AR (1)	AR089852A1 (es)
AU (1)	AU2013215254B2 (es)
CA (1)	CA2862332C (es)
CL (1)	CL2014002019A1 (es)
CO (1)	CO7020877A2 (es)
CY (2)	CY1121368T1 (es)
DK (2)	DK2809681T3 (es)
EA (1)	EA028647B1 (es)
ES (2)	ES2886123T3 (es)
HK (1)	HK1199269A1 (es)
HR (2)	HRP20211541T1 (es)
HU (2)	HUE056335T2 (es)
IL (2)	IL233410A0 (es)
IN (1)	IN2014CN04645A (es)
JO (1)	JO3547B1 (es)
LT (2)	LT2809681T (es)
MX (1)	MX358518B (es)
MY (1)	MY168748A (es)
NZ (1)	NZ626242A (es)
PH (1)	PH12014501613B1 (es)
PL (2)	PL2809681T3 (es)
PT (2)	PT3453723T (es)
RS (2)	RS58439B1 (es)
SG (1)	SG11201403222UA (es)
SI (2)	SI3453723T1 (es)
SM (1)	SMT202100628T1 (es)
TW (1)	TWI591073B (es)
UY (1)	UY34603A (es)
WO (1)	WO2013116296A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2862332C (en)	2012-01-31	2021-05-18	Regeneron Pharmaceuticals, Inc.	Anti-asic1 antibodies and uses thereof
US10272154B2 (en)	2014-04-15	2019-04-30	Sorrento Therapeutics, Inc.	Antigen binding proteins that bind WISP1
PT3248986T (pt)	2014-05-16	2022-04-05	Ablynx Nv	Domínios variáveis de imunoglobulina
CN105233286B (zh) *	2015-09-10	2018-10-30	上海交通大学医学院	含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) *	2016-02-26	2019-08-06	上海科技大学	一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) *	2016-11-01	2018-05-11	Berg Llc	Filamin b binding proteins and uses thereof
MD3638698T2 (ro) *	2018-01-26	2021-07-31	Regeneron Pharma	Anticorpi anti-TMPRSS2 și fragmente de legare al antigenului
US20230174642A1 (en) *	2019-06-04	2023-06-08	Shanghaitech University	AFFINITY-MATURATED ANTI-ASIC1a ANTIBODIES
CN118955717A (zh) *	2019-07-11	2024-11-15	纪念斯隆凯特琳癌症中心	Dll3靶向抗体及其用途
US20230287107A1 (en) *	2019-07-23	2023-09-14	Shanghaitech University	Asic1 channel antagonist antibody
MX2022003074A (es) *	2019-09-13	2022-06-14	Memorial Sloan Kettering Cancer Center	Anticuerpos anti-cd371, y usos de los mismos.
KR20240043784A (ko) *	2021-08-09	2024-04-03	메르크 파텐트 게엠베하	염증유발성 시토카인의 방출로부터 t 세포-매개 종양 세포독성을 디커플링시키는 단백질
CN118159558A (zh) *	2021-09-02	2024-06-07	纪念斯隆-凯特琳癌症中心	抗dll3抗体和其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2759373B1 (fr)	1997-02-11	2001-05-04	Centre Nat Rech Scient	Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ATE347596T1 (de)	1997-10-29	2006-12-15	Univ Mcgill	Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
US6287859B1 (en)	1998-08-05	2001-09-11	Centre National De La Recherche	Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en)	2000-04-20	2001-10-20	Philippe Seguela	A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en)	2000-04-25	2003-10-21	University Of Iowa Research Foundation	Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en)	2001-05-10	2006-11-07	Centre National De La Recherche Scientifique - Cnrs	Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) *	2001-07-18	2003-01-18	Philippe Seguela	Novel human proton gated ion channel
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20030186860A1 (en)	2002-03-29	2003-10-02	Welsh Michael J.	Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
JP2005530490A (ja) *	2002-03-29	2005-10-13	シェーリング　コーポレイション	インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物
US20070197583A1 (en)	2002-03-29	2007-08-23	Welsh Michael J	Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20070092444A1 (en) *	2003-09-11	2007-04-26	The Uab Research Foundation	Inhibition of inward sodium currents in cancer
WO2005074923A1 (en)	2004-02-03	2005-08-18	Agt Biosciences Limited	Methods and compositions
JP2007530664A (ja)	2004-03-30	2007-11-01	ペインセプターファーマコーポレーション	ゲートイオンチャンネルを調節するための組成物及び方法
JP5848861B2 (ja)	2004-04-20	2016-01-27	ジェンマブエー／エスＧｅｎｍａｂＡ／Ｓ	Ｃｄ２０に対するヒトモノクローナル抗体
US7192500B2 (en)	2004-04-30	2007-03-20	Kimberly-Clark Worldwide, Inc.	Process for making a garment including an absorbent assembly
US8030442B2 (en)	2004-09-16	2011-10-04	Morehouse School Of Medicine	Treatment of injury to the brain by inhibition of acid sensing ion channels
AU2005319382B2 (en) *	2004-12-21	2011-04-07	Astrazeneca Ab	Antibodies directed to angiopoietin-2 and uses thereof
GEP20115226B (en) *	2005-04-26	2011-06-10	Pfizer	P-cadherin antibodies
EP2374818B1 (en)	2006-06-02	2012-12-19	Regeneron Pharmaceuticals, Inc.	High affinity antibodies to human IL-6 receptor
JP5382692B2 (ja) *	2006-07-10	2014-01-08	学校法人藤田学園	抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
EP2043650A2 (en) *	2006-07-14	2009-04-08	Medical Research Council	Treatment for demyelinating disease
RU2448979C2 (ru)	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en)	2007-01-30	2009-10-06	Academia Sinica	Treatment of insulin resistance
ATE483985T1 (de)	2007-04-03	2010-10-15	Ilegusavnid Genetics Resource	Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
ES2465223T3 (es) *	2007-04-27	2014-06-05	Zymogenetics, Inc.	Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
EP2288922B1 (en) *	2008-05-08	2016-08-17	University of Utah Research Foundation	Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en)	2008-05-21	2009-11-26	University Of Iowa Research Foundation	Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr)	2008-06-06	2012-12-28	Centre Nat Rech Scient	Effets analgesiques de la toxine peptidique apetx2
WO2010054007A1 (en) *	2008-11-07	2010-05-14	Fabrus Llc	Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) *	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) *	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
GB0922434D0 (en) *	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
CN102234316B (zh) *	2010-05-07	2014-01-29	中国人民解放军军事医学科学院毒物药物研究所	具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en)	2012-01-31	2016-06-21	Regeneron Pharmaceuticals, Inc.	Anti-ASIC1 antibodies and uses thereof
CA2862332C (en)	2012-01-31	2021-05-18	Regeneron Pharmaceuticals, Inc.	Anti-asic1 antibodies and uses thereof

2013
- 2013-01-30 CA CA2862332A patent/CA2862332C/en active Active
- 2013-01-30 EP EP18201823.4A patent/EP3453723B1/en active Active
- 2013-01-30 EP EP13702876.7A patent/EP2809681B1/en active Active
- 2013-01-30 HU HUE18201823A patent/HUE056335T2/hu unknown
- 2013-01-30 SM SM20210628T patent/SMT202100628T1/it unknown
- 2013-01-30 KR KR1020147020682A patent/KR102111941B1/ko active IP Right Grant
- 2013-01-30 PL PL13702876T patent/PL2809681T3/pl unknown
- 2013-01-30 ES ES18201823T patent/ES2886123T3/es active Active
- 2013-01-30 SI SI201331923T patent/SI3453723T1/sl unknown
- 2013-01-30 JP JP2014554950A patent/JP6302844B2/ja active Active
- 2013-01-30 MY MYPI2014001721A patent/MY168748A/en unknown
- 2013-01-30 DK DK13702876.7T patent/DK2809681T3/en active
- 2013-01-30 DK DK18201823.4T patent/DK3453723T3/da active
- 2013-01-30 LT LTEP13702876.7T patent/LT2809681T/lt unknown
- 2013-01-30 EA EA201491452A patent/EA028647B1/ru not_active IP Right Cessation
- 2013-01-30 ES ES13702876T patent/ES2707599T3/es active Active
- 2013-01-30 HR HRP20211541TT patent/HRP20211541T1/hr unknown
- 2013-01-30 MX MX2014008541A patent/MX358518B/es active IP Right Grant
- 2013-01-30 NZ NZ626242A patent/NZ626242A/en unknown
- 2013-01-30 CN CN201380007553.3A patent/CN104093738B/zh active Active
- 2013-01-30 AR ARP130100280 patent/AR089852A1/es active IP Right Grant
- 2013-01-30 TW TW102103458A patent/TWI591073B/zh active
- 2013-01-30 PT PT182018234T patent/PT3453723T/pt unknown
- 2013-01-30 US US13/753,836 patent/US9150648B2/en active Active
- 2013-01-30 AU AU2013215254A patent/AU2013215254B2/en active Active
- 2013-01-30 RS RS20190287A patent/RS58439B1/sr unknown
- 2013-01-30 RS RS20211284A patent/RS62454B1/sr unknown
- 2013-01-30 SG SG11201403222UA patent/SG11201403222UA/en unknown
- 2013-01-30 IN IN4645CHN2014 patent/IN2014CN04645A/en unknown
- 2013-01-30 WO PCT/US2013/023784 patent/WO2013116296A1/en active Application Filing
- 2013-01-30 HU HUE13702876A patent/HUE042531T2/hu unknown
- 2013-01-30 LT LTEP18201823.4T patent/LT3453723T/lt unknown
- 2013-01-30 PT PT13702876T patent/PT2809681T/pt unknown
- 2013-01-30 PL PL18201823T patent/PL3453723T3/pl unknown
- 2013-01-30 JO JOP/2013/0036A patent/JO3547B1/ar active
- 2013-01-30 SI SI201331343T patent/SI2809681T1/sl unknown
- 2013-01-31 UY UY34603A patent/UY34603A/es not_active Application Discontinuation
2014
- 2014-06-26 IL IL233410A patent/IL233410A0/en unknown
- 2014-07-11 PH PH12014501613A patent/PH12014501613B1/en unknown
- 2014-07-25 CO CO14162499A patent/CO7020877A2/es unknown
- 2014-07-30 CL CL2014002019A patent/CL2014002019A1/es unknown
- 2014-12-23 HK HK14112815.2A patent/HK1199269A1/xx unknown
2015
- 2015-09-09 US US14/848,452 patent/US20160002332A1/en not_active Abandoned
2017
- 2017-09-11 IL IL254416A patent/IL254416B/en active IP Right Grant
- 2017-09-28 US US15/719,220 patent/US10513557B2/en active Active
2019
- 2019-02-22 HR HRP20190358TT patent/HRP20190358T1/hr unknown
- 2019-02-27 CY CY20191100246T patent/CY1121368T1/el unknown
2021
- 2021-11-09 CY CY20211100968T patent/CY1124778T1/el unknown

Also Published As

Publication number	Publication date
JP2015508063A (ja)	2015-03-16
MX358518B (es)	2018-08-24
US20130195878A1 (en)	2013-08-01
KR20140125363A (ko)	2014-10-28
IL254416A0 (en)	2017-11-30
HUE042531T2 (hu)	2019-07-29
HUE056335T2 (hu)	2022-02-28
US9150648B2 (en)	2015-10-06
CN104093738B (zh)	2018-05-18
PT2809681T (pt)	2019-02-18
AR089852A1 (es)	2014-09-24
SI2809681T1 (sl)	2019-04-30
PT3453723T (pt)	2021-09-07
CA2862332C (en)	2021-05-18
AU2013215254A1 (en)	2014-07-03
LT3453723T (lt)	2021-09-10
EP3453723B1 (en)	2021-08-11
CY1121368T1 (el)	2020-05-29
JO3547B1 (ar)	2020-07-05
TW201335182A (zh)	2013-09-01
BR112014018651A2 (pt)	2017-07-04
PH12014501613A1 (en)	2014-10-13
ES2707599T3 (es)	2019-04-04
MX2014008541A (es)	2014-10-24
CA2862332A1 (en)	2013-08-08
CO7020877A2 (es)	2014-08-11
EA028647B1 (ru)	2017-12-29
SMT202100628T1 (it)	2022-01-10
JP6302844B2 (ja)	2018-03-28
MY168748A (en)	2018-11-30
SI3453723T1 (sl)	2021-11-30
US20180222976A1 (en)	2018-08-09
SG11201403222UA (en)	2014-07-30
LT2809681T (lt)	2019-02-11
NZ626242A (en)	2017-02-24
AU2013215254B2 (en)	2017-08-31
KR102111941B1 (ko)	2020-05-18
PL2809681T3 (pl)	2019-05-31
EP2809681A1 (en)	2014-12-10
EP3453723A2 (en)	2019-03-13
US20160002332A1 (en)	2016-01-07
US10513557B2 (en)	2019-12-24
UY34603A (es)	2013-07-31
ES2886123T3 (es)	2021-12-16
HK1199269A1 (en)	2015-06-26
IN2014CN04645A (es)	2015-09-18
PL3453723T3 (pl)	2022-01-03
HRP20190358T1 (hr)	2019-04-05
IL254416B (en)	2018-03-29
CY1124778T1 (el)	2022-11-25
DK3453723T3 (da)	2021-09-13
PH12014501613B1 (en)	2014-10-13
EA201491452A1 (ru)	2014-11-28
IL233410A0 (en)	2014-08-31
EP2809681B1 (en)	2018-12-05
WO2013116296A1 (en)	2013-08-08
TWI591073B (zh)	2017-07-11
HRP20211541T1 (hr)	2021-12-24
EP3453723A3 (en)	2019-04-10
RS58439B1 (sr)	2019-04-30
RS62454B1 (sr)	2021-11-30
CN104093738A (zh)	2014-10-08
DK2809681T3 (en)	2019-03-11

Publication	Publication Date	Title
CL2014003136A1 (es)	2015-02-27	Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2014002019A1 (es)	2015-01-16	Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2014002954A1 (es)	2015-02-06	Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
CL2016000251A1 (es)	2017-07-14	Anticuerpos anti-activina y usos de los mismos
CL2014002549A1 (es)	2015-01-16	Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
BR112015002790A2 (pt)	2017-08-08	anticorpos asgpr e usos dos mesmos.
CL2016002569A1 (es)	2017-09-08	Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112015001459A2 (pt)	2017-07-04	anticorpos anti-kit e usos dos mesmos.
CL2016002252A1 (es)	2017-06-30	Anticuerpos anti-egfrviii y usos de los mismos
CL2015001924A1 (es)	2016-06-10	Anticuerpos anti-pdgfr-beta y usos relacionados.
CR20150380A (es)	2015-08-21	Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CO7020859A2 (es)	2014-08-11	Anticuerpos anti-cd134 (ox40) y usos de los mismos
DK3030262T3 (da)	2019-12-02	Kombineret farmaceutisk sammensætning
CO6821892A2 (es)	2013-12-31	Anticuerpos anti-angptl3 y usos de los mismos
CO7061078A2 (es)	2014-09-19	Compuestos de enediino, conjugados de los mismos y sus usos y metodos
CL2015000027A1 (es)	2015-07-10	Anticuerpos e inmunoconjugados anti-cd22
CL2014002616A1 (es)	2015-01-30	Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos.
BR112014029403A2 (pt)	2018-10-09	conjugados, anticorpo e formulação farmacêutica
DK3181122T3 (da)	2023-06-06	Farmaceutisk dasatinib-sammensætning
BR112014028602A2 (pt)	2017-06-27	formulação líquida.
BR112015002738A2 (pt)	2018-05-22	composto , e , composição farmacêutica
BR112015003259A2 (pt)	2017-08-08	composto, composição farmacêutica, e, composição de vacina.
DK2897594T3 (da)	2020-06-29	Farmaceutisk sammensætning
BR112014026357A2 (pt)	2017-06-27	composição e sistema